BA
VNDA icon

Boston Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Boston Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,515
Closed -$278K – 669
2017
Q3 		$278K Sell
15,515
-335
-2% -$5.61K 0.01% 581
2017
Q2 		$258K Sell
15,850
-20,230
-56% -$292K 0.01% 599
2017
Q1 		$505K Sell
36,080
-2,785
-7% -$39.7K 0.01% 467
2016
Q4 		$620K Buy
38,865
+6,195
+19% +$99.6K 0.01% 437
2016
Q3 		$544K Sell
32,670
-3,520
-10% -$47.4K 0.01% 488
2016
Q2 		$405K Buy
36,190
+245
+0.7% +$2.37K 0.01% 529
2016
Q1 		$301K Buy
35,945
+380
+1% +$3.12K 0.01% 587
2015
Q4 		$331K Hold
35,565
– – 0.01% 556
2015
Q3 		$401K Buy
+35,565
New +$435K 0.02% 586

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Advisors's VNDA Position: Q4 2017 in Review

Boston Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2017, closing a stake of 15,515 shares — an estimated $278K sold.

Boston Advisors first reported a position in VNDA in Q3 2015 and held it in 9 quarters. The position peaked at $620K in Q4 2016. 125 funds tracked by Wall St. Rank hold VNDA as of Q4 2017.

  • Boston Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Boston Advisors sold 15,515 Vanda Pharmaceuticals shares in Q4 2017, an estimated $278K.
  • Boston Advisors first reported a position in Vanda Pharmaceuticals in Q3 2015 and held it in 9 quarters.
  • Boston Advisors's Vanda Pharmaceuticals position peaked at $620K in Q4 2016.
  • 125 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2017.

Based on Boston Advisors's 13F filing for Q4 2017, filed 24 Jan 2018.